Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trials

References

• Aslan JE, Tormoen GW, Loren CP, et al. (2011). S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 118:3129–36.
   PubMed Web of Science ®Google Scholar
• Asor E, Ben-Shachar D. (2012). Platelets: a possible glance into brain biological processes in schizophrenia. World J Psychiatry 2:124–33.
   PubMedGoogle Scholar
• Baier PC, Koch JM, Seeck-Hirschner M, et al. (2009). A flow-cytometric method to investigate glutamate-receptor-sensitivity in whole blood platelets – results from healthy controls and patients with schizophrenia. J Psychiatr Res 43:585–91.
   PubMed Web of Science ®Google Scholar
• Bassell GJ, Warren ST. (2008). Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 60:201–14.
   PubMed Web of Science ®Google Scholar
• Bear MF, Dolen G, Osterweil E, Nagarajan N. (2008). Fragile X: translation in action. Neuropsychopharmacology 33:84–7.
   PubMed Web of Science ®Google Scholar
• Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG. (2006). Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem 281:32072–80.
   PubMed Web of Science ®Google Scholar
• Berk M. (2005) Platelet glutamate receptors as a window into psychiatric disorders. In: Gill S, Pulido O, eds. Glutamate receptors in peripheral tissue: excitatory transmission outside the CNS. Vol. 1. New York: Springer, 233–41.
   Google Scholar
• Berk M, Plein H, Belsham B. (2000). The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci 66:2427–32.
   PubMed Web of Science ®Google Scholar
• Berk M, Plein H, Csizmadia T. (1999). Supersensitive platelet glutamate receptors as a possible peripheral marker in schizophrenia. Int Clin Psychopharmacol 14:119–22.
   PubMed Web of Science ®Google Scholar
• Berk M, Plein H, Ferreira D. (2001). Platelet glutamate receptor supersensitivity in major depressive disorder. Clin Neuropharmacol 24:129–32.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hessl D, Abbeduto L, et al. (2013). Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr 34:508–22.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Hicar M, Ciurlionis R. (1995). Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. Pediatr Res 38:638–43.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Huttenlocher PR. (1992). Cyclic AMP metabolism in fragile X syndrome. Ann Neurol 31:22–6.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Knox A, Hervey C. (2011). Targeted treatments for fragile X syndrome. J Neurodev Disord 3:193–210.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Sklena P. (1993). Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. Am J Med Genet 45:81–7.
   PubMed Web of Science ®Google Scholar
• Berry-Kravis E, Sumis A, Hervey C, et al. (2008). Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 29:293–302.
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Kaphzan H, Alvarez-Dieppa AC, et al. (2012). Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76:325–37.
   PubMed Web of Science ®Google Scholar
• Borroni B, Colciaghi F, Pastorino L, et al. (2002). ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. Eur Neuropsychopharmacol 12:195–200.
   PubMed Web of Science ®Google Scholar
• Boyanova D, Nilla S, Birschmann I, et al. (2012). PlateletWeb: a systems biologic analysis of signaling networks in human platelets. Blood 119:e22–34.
   PubMedGoogle Scholar
• Caku A, Pellerin D, Bouvier P, et al. (2014). Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study. Am J Med Genet A 164A:2834–42.
   PubMed Web of Science ®Google Scholar
• Camacho A, Dimsdale JE. (2000). Platelets and psychiatry: lessons learned from old and new studies. Psychosom Med 62:326–36.
   PubMed Web of Science ®Google Scholar
• Cao Z, Liu L, Packwood W, et al. (2008). Sex differences in the mechanism of Met5-enkephalin-induced cardioprotection: role of PI3K/Akt. Am J Physiol Heart Circ Physiol 294:H302–10.
   PubMed Web of Science ®Google Scholar
• Catricala S, Torti M, Ricevuti G. (2012). Alzheimer disease and platelets: how’s that relevant. Immun Ageing 9:20.
   PubMed Web of Science ®Google Scholar
• Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, Bragado MJ. (2005). Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 94:1277–87.
   PubMed Web of Science ®Google Scholar
• Cerezo-Guisado MI, Garcia-Roman N, Garcia-Marin LJ, et al. (2007). Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J 401:175–83.
   PubMed Web of Science ®Google Scholar
• Clarke WP, Chavera TA, Silva M, et al. (2013). Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol 170:532–45.
   PubMed Web of Science ®Google Scholar
• Cocchi M, Tonello L, Gabrielli F. (2012). Considerations on blood platelets: a neuron’s mirror for mood disorders? Open J Blood Dis 2:22–9.
   Google Scholar
• Cohen JA, Leeksma CH. (1956). Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate. J Clin Invest 35:964–9.
   PubMed Web of Science ®Google Scholar
• Colak D, Zaninovic N, Cohen MS, et al. (2014). Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. Science 343:1002–5.
   PubMed Web of Science ®Google Scholar
• Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. (2009). Translational control of long-lasting synaptic plasticity and memory. Neuron 61:10–26.
   PubMed Web of Science ®Google Scholar
• Danovich L, Weinreb O, Youdim MBH, Silver H. (2012). Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. Psychopharmacology (Berl) 220:763–70.
   PubMed Web of Science ®Google Scholar
• Darnell JC, Klann E. (2013). The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 16:1530–6.
   PubMed Web of Science ®Google Scholar
• Darnell JC, Van Driesche SJ, Zhang C, et al. (2011). FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247–61.
   PubMed Web of Science ®Google Scholar
• Das I, Khan NS, Puri BK, et al. (1995). Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212:375–80.
   PubMed Web of Science ®Google Scholar
• Di Benedetto B, Radecke J, Schmidt MV, Rupprecht R. (2013). Acute antidepressant treatment differently modulates ERK/MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex. Neuroscience 232:161–8.
   PubMed Web of Science ®Google Scholar
• Dolen G, Carpenter RL, Ocain TD, Bear MF. (2010). Mechanism-based approaches to treating fragile X. Pharmacol Therapeut 127:78–93.
   PubMed Web of Science ®Google Scholar
• Ehrlich D, Humpel C. (2012). Platelets in psychiatric disorders. World J Psychiatry 2:91–4.
   PubMedGoogle Scholar
• Engel SR, Creson TK, Hao Y, et al. (2009). The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol Psychiatry 14:448–61.
   PubMed Web of Science ®Google Scholar
• Erickson CA, Weng N, Weiler IJ, et al. (2011). Open-label riluzole in fragile X syndrome. Brain Res 1380:264–70.
   PubMed Web of Science ®Google Scholar
• Fasano S, Brambilla R. (2011). Ras-ERK signaling in behavior: old questions and new perspectives. Front Behav Neurosci 5:79.
   PubMed Web of Science ®Google Scholar
• Fu YH, Kuhl DP, Pizzuti A, et al. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67:1047–58.
   PubMed Web of Science ®Google Scholar
• Fumagalli F, Cattaneo A, Caffino L, et al. (2010). Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 62:523–9.
   PubMed Web of Science ®Google Scholar
• Gallagher SM, Daly CA, Bear MF, Huber KM. (2004). Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J Neurosci 24:4859–64.
   PubMed Web of Science ®Google Scholar
• Garcia A, Quinton TM, Dorsam RT, Kunapuli SP. (2005). Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets. Blood 106:3410–14.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Lu G, Su G, et al. (2014). Phosphorylation of Akt and abdominal aortic aneurysm formation. Am J Pathol 184:148–58.
   PubMed Web of Science ®Google Scholar
• Giachini FR, Sullivan JC, Lima VV, et al. (2010). Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediates sex differences in desoxycorticosterone acetate-salt hypertension vascular reactivity. Hypertension 55:172–9.
   PubMed Web of Science ®Google Scholar
• Gross C, Bassell GJ. (2012). Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110β-selective inhibitor. Mol Med 18:336–45.
   PubMed Web of Science ®Google Scholar
• Gross C, Nakamoto M, Yao X, et al. (2010). Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 30:10624–38.
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Klann E. (2010). mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33:67–75.
   PubMed Web of Science ®Google Scholar
• Hoeffer CA, Sanchez E, Hagerman RJ, et al. (2012). Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav 11:332–41.
   PubMed Web of Science ®Google Scholar
• Horwood JM, Dufour F, Laroche S, Davis S. (2006). Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat. Eur J Neurosci 23:3375–84.
   PubMed Web of Science ®Google Scholar
• Hou L, Antion MD, Hu D, et al. (2006). Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51:441–54.
   PubMed Web of Science ®Google Scholar
• Hou L, Klann E. (2004). Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J Neurosci 24:6352–61.
   PubMed Web of Science ®Google Scholar
• Hsu YT, Liao G, Bi X, et al. (2011). The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices. Neuropharmacology 61:1275–81.
   PubMed Web of Science ®Google Scholar
• Hu H, Qin Y, Bochorishvili G, et al. (2008). Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 28:7847–62.
   PubMed Web of Science ®Google Scholar
• Hunter RW, Mackintosh C, Hers I. (2009). Protein kinase C-mediated phosphorylation and activation of PDE3A regulate cAMP levels in human platelets. J Biol Chem 284:12339–48.
   PubMed Web of Science ®Google Scholar
• Ishisaka M, Kakefuda K, Oyagi A, et al. (2012). Diacylglycerol kinase β knockout mice exhibit attention-deficit behavior and an abnormal response on methylphenidate-induced hyperactivity. PLoS One 7:e37058.
   PubMed Web of Science ®Google Scholar
• Kauskot A, Hoylaerts MF. (2012). Platelet receptors. Handb Exp Pharmacol 210:23–57.
   PubMedGoogle Scholar
• Kelley DJ, Davidson RJ, Elliott JL, et al. (2007). The cyclic AMP cascade is altered in the fragile X nervous system. PLoS One 2:e931.
   PubMed Web of Science ®Google Scholar
• Kim JI, Lee HR, Sim SE, et al. (2011). PI3Kγ is required for NMDA receptor-dependent long-term depression and behavioral flexibility. Nat Neurosci 14:1447–54.
   PubMed Web of Science ®Google Scholar
• Kim SH, Markham JA, Weiler IJ, Greenough WT. (2008). Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc Natl Acad Sci USA 105:4429–34.
   PubMed Web of Science ®Google Scholar
• Kimoto S, Okuda A, Toritsuka M, et al. (2011). Olanzapine stimulates proliferation but inhibits differentiation in rat oligodendrocyte precursor cell cultures. Prog Neuropsychopharmacol Biol Psychiatry 35:1950–6.
   PubMed Web of Science ®Google Scholar
• Kosty J, Riley J, Liang J, Armstead WM. (2012). Influence of sex and ERK MAPK on the pressure reactivity index in newborn piglets after fluid percussion injury. Transl Stroke Res 3:460–5.
   PubMed Web of Science ®Google Scholar
• Kottke-Marchant K, Corcoran G. (2002). The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 126:133–46.
   PubMed Web of Science ®Google Scholar
• Kumar V, Zhang MX, Swank MW, et al. (2005). Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25:11288–99.
   PubMed Web of Science ®Google Scholar
• Kumari D, Bhattacharya A, Nadel J, et al. (2014). Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum Mutat 35:1485–94.
   PubMed Web of Science ®Google Scholar
• Kumari R, Castillo C, Francesconi A. (2013). Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domains. J Biol Chem 288:32004–19.
   PubMed Web of Science ®Google Scholar
• Lang F, Munzer P, Gawaz M, Borst O. (2013). Regulation of STIM1/Orai1-dependent Ca2+ signalling in platelets. Thromb Haemostasis 110:925–30.
   PubMed Web of Science ®Google Scholar
• Lee YM, Chen WF, Chou DS, et al. (2010). Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci 17:45.
   PubMed Web of Science ®Google Scholar
• Lessard M, Chouiali A, Drouin R, et al. (2012). Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. Clin Genet 82:472–7.
   PubMed Web of Science ®Google Scholar
• Li W, Cui Y, Kushner SA, et al. (2005). The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961–7.
   PubMed Web of Science ®Google Scholar
• Li Z, Delaney MK, O’Brien KA, Du X. (2010). Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30:2341–9.
   PubMed Web of Science ®Google Scholar
• Lin KH, Lu WJ, Wang SH, et al. (2014). Characteristics of endogenous γ-aminobutyric acid (GABA) in human platelets: functional studies of a novel collagen glycoprotein VI inhibitor. J Mol Med 92:603–14.
   PubMed Web of Science ®Google Scholar
• Lugo JN, Smith GD, Arbuckle EP, et al. (2014). Deletion of PTEN produces autism-like behavioral deficits and alterations in synaptic proteins. Front Mol Neurosci 7:27.
   PubMed Web of Science ®Google Scholar
• Mangano RM, Schwarcz R. (1981). The human platelet as a model for the glutamatergic neuron: platelet uptake of L-glutamate. J Neurochem 36:1067–76.
   PubMed Web of Science ®Google Scholar
• McNicol A, Jackson EC. (2003). Inhibition of the MEK/ERK pathway has no effect on agonist-induced aggregation of human platelets. Biochem Pharmacol 65:1243–50.
   PubMed Web of Science ®Google Scholar
• Michalon A, Sidorov M, Ballard TM, et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49–56.
   PubMed Web of Science ®Google Scholar
• Mines MA, Jope RS. (2012). Brain region differences in regulation of Akt and GSK3 by chronic stimulant administration in mice. Cell Signal 24:1398–405.
   PubMed Web of Science ®Google Scholar
• Nadal-Wollbold F, Pawlowski M, Levy-Toledano S, et al. (2002). Platelet ERK2 activation by thrombin is dependent on calcium and conventional protein kinases C but not Raf-1 or B-Raf. FEBS Lett 531:475–82.
   PubMed Web of Science ®Google Scholar
• Niu H, Chen X, Gruppo RA, et al. (2012). Integrin αIIb-mediated PI3K/Akt activation in platelets. PLoS One 7:e47356.
   PubMed Web of Science ®Google Scholar
• Osterweil EK, Chuang SC, Chubykin AA, et al. (2013). Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77:243–50.
   PubMed Web of Science ®Google Scholar
• Osterweil EK, Krueger DD, Reinhold K, Bear MF. (2010). Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30:15616–27.
   PubMed Web of Science ®Google Scholar
• Pan HY, DeVault AR, Wang-Iverson D, et al. (1990). Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 30:1128–35.
   PubMed Web of Science ®Google Scholar
• Park SW, Lee JG, Seo MK, et al. (2014). Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons. Int J Neuropsychoph 17:1831–46.
   PubMed Web of Science ®Google Scholar
• Pereira A, Zhang B, Malcolm P, et al. (2014). Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. BMC Neurosci 15:30.
   PubMed Web of Science ®Google Scholar
• Plein H, Berk M. (2001). The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol 16:229–36.
   PubMed Web of Science ®Google Scholar
• Price TJ, Rashid MH, Millecamps M, et al. (2007). Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci 27:13958–67.
   PubMed Web of Science ®Google Scholar
• Procaccia S, Kraus S, Seger R. (2010). Determination of ERK activity: anti-phospho-ERK antibodies and in vitro phosphorylation. Methods Mol Biol 661:39–58.
   PubMedGoogle Scholar
• Sharma A, Hoeffer CA, Takayasu Y, et al. (2010). Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30:694–702.
   PubMed Web of Science ®Google Scholar
• Taler M, Miron O, Gil-Ad I, Weizman A. (2013). Neuroprotective and procognitive effects of sertraline: in vitro and in vivo studies. Neurosci Lett 550:93–7.
   PubMed Web of Science ®Google Scholar
• Talib LL, Joaquim HP, Forlenza OV. (2012). Platelet biomarkers in Alzheimer’s disease. World J Psychiatry 2:95–101.
   PubMedGoogle Scholar
• Thibault A, Samid D, Tompkins AC, et al. (1996). Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483–91.
   PubMed Web of Science ®Google Scholar
• Thomas GM, Huganir RL. (2004). MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5:173–83.
   PubMed Web of Science ®Google Scholar
• Verkerk AJ, Pieretti M, Sutcliffe JS, et al. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905–14.
   PubMed Web of Science ®Google Scholar
• Wang X, Snape M, Klann E, et al. (2012). Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile x-syndrome. J Neurochem 121:672–9.
   PubMed Web of Science ®Google Scholar
• Weiler IJ, Spangler CC, Klintsova AY, et al. (2004). Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci USA 101:17504–9.
   PubMed Web of Science ®Google Scholar
• Weng N, Weiler IJ, Sumis A, et al. (2008). Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet 147B:1253–7.
   PubMed Web of Science ®Google Scholar
• Wu GY, Deisseroth K, Tsien RW. (2001). Spaced stimuli stabilize MAPK pathway activation and its effects on dendritic morphology. Nat Neurosci 4:151–8.
   PubMed Web of Science ®Google Scholar
• Wylie-Sears J, Levine RA, Bischoff J. (2014). Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-beta-induced phosphorylation of ERK. Biochem Biophys Res Commun 446:870–5.
   PubMed Web of Science ®Google Scholar
• Yabuki Y, Shioda N, Maeda T, et al. (2014). Aberrant CaMKII activity in the medial prefrontal cortex is associated with cognitive dysfunction in ADHD model rats. Brain Res 1557:90–100.
   PubMed Web of Science ®Google Scholar
• Zhang HT. (2009). Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Design 15:1688–98.
   PubMed Web of Science ®Google Scholar
• Zhang HT, Huang Y, Masood A, et al. (2008). Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology 33:1611–23.
   PubMed Web of Science ®Google Scholar
• Zhang HT, Zhao Y, Huang Y, et al. (2004). Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432–9.
   PubMed Web of Science ®Google Scholar